HomeBusinessHealthcareAxoGen (AXGN) CEO On Positive Topline Results For Avance Nerve Graft Product
AxoGen (AXGN) CEO On Positive Topline Results For Avance Nerve Graft Product

AxoGen (AXGN) stock price today was up over 6%. AxoGen is a developer and marketer of surgical solutions for peripheral nerve injuries. Recently, AxoGen announced positive topline results for Avance Nerve Graft product. Chairman and CEO Karen Zaderej weighs in on nerve grafting and the recent AxoGen earnings report that indicated $31M in revenue. How will this healthcare stock perform moving forward?

The Watch List

13 May 2022

ON AIR
8:00 am
Morning Trade Live
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
ON AIR
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US